Fidelity Investments
CUE icon

Fidelity Investments’s Cue Biopharma CUE Stock Holding History

Fidelity Investments’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3
Closed -$105 – 5363
2024
Q4 		$105 Sell
3
-7
-70% -$263 ﹤0.01% 5101
2024
Q3 		$216 Sell
10
-238
-96% -$5.16K ﹤0.01% 5030
2024
Q2 		$9.22K Buy
248
+150
+153% +$7.42K ﹤0.01% 4359
2024
Q1 		$5.56K Sell
98
-129
-57% -$9.1K ﹤0.01% 4473
2023
Q4 		$18K Buy
227
+168
+285% +$12K ﹤0.01% 4000
2023
Q3 		$4.1K Sell
59
-104
-64% -$10.2K ﹤0.01% 4379
2023
Q2 		$17.9K Buy
163
+15
+10% +$1.76K ﹤0.01% 3913
2023
Q1 		$15.8K Buy
148
+132
+825% +$12.6K ﹤0.01% 3945
2022
Q4 		$1.38K Buy
+16
New +$1.46K ﹤0.01% 4594
2022
Q3 		– Hold
0
– – – 4924
2022
Q2 		– Sell
-37
Closed -$4.33K – 4978
2022
Q1 		$5K Buy
+37
New +$7.85K ﹤0.01% 4420

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments's CUE Position: Q1 2025 in Review

Fidelity Investments sold out of Cue Biopharma (CUE) in Q1 2025, closing a stake of 3 shares — an estimated $105 sold.

Fidelity Investments first reported a position in CUE in Q1 2022 and held it in 10 quarters. The position peaked at $18K in Q4 2023. 49 funds tracked by Wall St. Rank hold CUE as of Q1 2025.

  • Fidelity Investments reported no remaining Cue Biopharma position as of Q1 2025 after selling out during the quarter.
  • Fidelity Investments sold 3 Cue Biopharma shares in Q1 2025, an estimated $105.
  • Fidelity Investments first reported a position in Cue Biopharma in Q1 2022 and held it in 10 quarters.
  • Fidelity Investments's Cue Biopharma position peaked at $18K in Q4 2023.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2025.

Based on Fidelity Investments's 13F filing for Q1 2025, filed 12 May 2025.